An interventional study of Aminoguanidine and Placebos in Asthma, sponsored by Imperial College London. Completed at 1 site in United Kingdom. Open to participants aged 21 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-10.
Sponsored by Imperial College London · Not applicable, Interventional, and Treatment
The primary aim of this study is to investigate the effects of oral and inhaled administration of L-arginine and of inhaled aminoguanidine on bronchial and alveolar exhaled NO and NO metabolites in exhaled breath condensate, saliva and nasal lavage fluid in normal and asthmatic subjects.
Nitric oxide (NO) is produced by a variety of cells within the respiratory tract, particularly airway epithelial cells, and its increased concentration in asthma is likely to derive from inducible NO synthase (iNOS) expressed in inflamed airways. To evaluate whether an increased bronchial flux of NO (ie, airway wall NO flux [Jno] in picoliters per second) produced in the large airways is due to an enzyme overexpression, we administered a relatively selective iNOS inhibitor, aminoguanidine, by nebulization in a double-blind, placebo-controlled manner in asthmatic and healthy subjects and also investigated whether the same concentration of inhibitor has any effect on NO produced in the peripheral lungs (ie, alveolar NO concentration [Calv] in parts per billion [ppb]) or on the diffusing capacity of NO (Dno) [in picoliters per second-1 per ppb-1) in the airways. Aminoguanidine administration resulted in a significant reduction in Jno compared with administration of the saline solution control in eight healthy subjects and in eight patients with asthma but caused no significant changes in Calv or in Dno in either group.
3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.
This study's enrollment of 16 is below the median of 83 across 2,752 interventional studies indexed under Asthma.
Browse Asthma studies →Imperial College London is the lead sponsor of 824 studies on the registry; 178 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Healthy non-smokers (n=10):
Asthmatic subjects (n=15):
Exclusion Criteria:
8 non smokers non asthmatic
Drug: Placebos
8 asthmatic mild
Drug: Aminoguanidine
500mg
Also known as: Inhalation of aminoguanidine
2ml
Also known as: Nebulase saline solution
Bronchial exhale nitric oxide
Bronchial exhale nitric oxide (JNo) assessed by chemo luminescence
Time frame: 6 hours
Peripheral exhaled nitric oxide
Peripheral exhaled nitric oxide(CALV) assessed by chemo luminescence
Time frame: 6 hours
Plan to share: No
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Imperial College London